Renaissance of an “old” vaccine

In 2014, the Strategic Advisory Group of Experts (SAGE) on Immunization endorsed a new routine vaccination schedule to optimise poliomyelitis prevention after the switch from trivalent to bivalent types 1 and 3 OPV (bOPV).10 This schedule calls for one dose of IPV after multiple doses of bOPV, to mi...

Full description

Saved in:
Bibliographic Details
Published in:The Lancet infectious diseases 2016-03, Vol.16 (3), p.268-270
Main Authors: Sutter, Roland W, Kew, Olen M
Format: Article
Language:English
Subjects:
Female
Humans
Immunization
Infectious Disease
Infectious diseases
Licenses
Male
Poliomyelitis
Poliomyelitis - prevention & control
Poliovirus - immunology
Poliovirus Vaccine, Inactivated - adverse effects
Poliovirus Vaccine, Inactivated - immunology
Vaccines
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In 2014, the Strategic Advisory Group of Experts (SAGE) on Immunization endorsed a new routine vaccination schedule to optimise poliomyelitis prevention after the switch from trivalent to bivalent types 1 and 3 OPV (bOPV).10 This schedule calls for one dose of IPV after multiple doses of bOPV, to mitigate the paralytic consequences of circulating vaccine-derived poliovirus type 2 after the switch, and close the remaining immunity gaps to poliovirus types 1 and 3. When countries use only IPV, no new circulating vaccine-derived polioviruses, vaccine-associated paralytic poliomyelitis, or prolonged excretion of poliovirus in immunodeficient individuals will be generated, and IPV will contribute to secure the final eradication of poliomyelitis.
ISSN:1473-3099
1474-4457
DOI:10.1016/S1473-3099(15)00526-5